https://orcid.org/0000-0001-8369-5044
Figures & data
Figure 1. Model structure.
Abbreviations: 1L: First-line; 2L: Second-line; 3L: Third-line; DAS28: Disease Activity Score 28; Tx: Treatment
Figure 2. Treatment algorithm.
Abbreviations: DMARD: Disease modifying anti-rheumatic drug
Table 6. Cost breakdown and health outcomes with Upadacitinib - Scenario 2 (severe RA).
Figure 3. Total societal cost and QALY with upadacitinib – Scenario 1.
Abbreviations: RA: Rheumatoid Arthritis; SAR: Saudi Riyal; QALY: Quality-adjusted Life-year
Table 1. Health outcomes with Upadacitinib - Scenario 1.
Table 2. Cost breakdown and health outcomes with Upadacitinib - Scenario 1 (moderate RA).
Table 3. Cost breakdown and health outcomes with Upadacitinib - Scenario 1 (severe RA).
Figure 4. Total societal cost and QALY with upadacitinib – Scenario 2.
Abbreviations: RA: Rheumatoid Arthritis; SAR: Saudi Riyal; QALY: Quality-adjusted Life-year
Table 4. Health outcomes with Upadacitinib - Scenario 2.
Table 5. Cost breakdown and health outcomes with Upadacitinib - Scenario 2 (moderate RA).
Supplemental Material
Download MS Word (1.5 MB)Data availability statement
The data that support the findings of this study are available from the corresponding author, MA, upon reasonable request.